🎉Congratulations to Cambridge-based Maxion Therapeutics on their milestone fundraising of £58 ($72)million, one of the largest private biotech financings in Europe since early 2024!🎉

Leveraging our proprietary valuation model, we estimate Maxion’s market value at £107-145million, reflecting the tremendous potential of its cutting-edge KnotBody technology and development pipeline. This valuation also recognises the company’s highly respected biotech founders, a leadership team with deep expertise in antibody-based drug discovery and development, and its access to large global markets.

This oversubscribed Series A round was led by General Catalyst, with additional investment from new investors British Businese Bank, Patient Capital, Solasta Ventures, and Eli Lilly and Company, alongside continued support from existing investors LifeArc Ventures, Monograph Capital, and BGF.

About Maxion Therapeutics
Maxion Therapeutics is a biotechnology company pioneering antibody-based drugs for previously untreatable ion channel- and G protein-coupled receptor (GPCR)-driven diseases, including autoimmune conditions, chronic pain, and cardiovascular disease.

The company is advancing a pipeline of potentially first- and best-in-class therapeutics using its proprietary KnotBody technology, which combines naturally occurring mini-proteins (‘knottins’) with antibodies through state-of-the-art phage and mammalian display technologies. This approach enables the development of potent, selective, and long-acting therapeutics.

Founded in 2020 by distinguished biotech entrepreneurs and scientists Dr. John McCafferty (CTO) and Dr. Aneesh Karatt-Vellatt (CSO), Maxion benefits from deep scientific expertise. Dr. McCafferty co-invented antibody phage display, a breakthrough technology that contributed to the 2018 Nobel Prize in Chemistry, awarded to his co-inventor Sir Gregory Winter.

No matter you are a startup or an investor, feel free to get in touch with our team to learn more about our valuation services!